Shares of China's CanSino Biologics rise as much as 15% on Wednesday afternoon.
Cansino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable.
康希诺生物日内走高,一度涨超15%,此前宣布与Aerogen合作开发全球首款吸入式新冠疫苗。
$康希诺生物 (06185.HK)$ $康希诺 (688185.SH)$